Johnson & Johnson ( JNJ 0.01%) has been a leading healthcare company in the world for decades, and it's one of the most ...

The three philanthropists devoted themselves and their resources to important causes during lifetimes of service to Palm ...

Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study.

Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.

Johnson & Johnson's 2025 outlook sees slight EPS and revenue upgrades, while headwinds from biosimilars and tariffs are expected to weigh on performance.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Premier Strategy” ...

So, I can't, in good conscience, suggest anyone buy Johnson & Johnson because I wouldn't buy the stock myself right now. Should you invest $1,000 in Johnson & Johnson right now?

Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...

A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Jo ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on ...